Newsfilter article unlocker

Good afternoon. My name is Sarah Conrad, and I'm on the GS Healthcare Services team here. Today I am joined by Doc Goh and CEO Lee Beamstock. Lee, just for those who are a little less familiar with the story, can you give a high-level overview of the business today and how we're thinking about the core value proposition? Absolutely, Sarah. It's great to be here with you. So for those less familiar mit Doc Go, essentially we deliver healthcare, literally. We go into patients' homes and deliver healthcare. We provide virtual care services, remote care services and we also have a very large medical transportation business where we go and take patients from one care setting to the next. So that's essentially what our company is there to do. We're going to meet patients where they are or bring patients to where they need to get to and we do that at great scale. Last year we transported 700,000 patients and we visited about 150,000 patients in the home and did over a million telehealth visits. So we're really excited, we're meeting patients where they are. And we think when you meet patients where they are, you have better health outcomes, you have better help outcomes. Obviously, it's great for the patients, it is great for the system, and we think we'll do well in that in that way. Yeah, so the company's gone through a bit of transition over the last couple years. You've moved away from your COVID and migrant-related work. Can you talk about the main pieces of the business today and how investors should think about like what the normalized business should look like from here? Absolutely. So you mentioned it. I mean, the company went public in 2021. At that time, we were a medical transportation company. We've been doing medical transportation now for over 10 years. When the company went public, we Were doing about $100 million of medical transportation revenue in that year. This year, we'll do over 200 million. So we've doubled the medical transportation business in that time. And at the time, we were doing a lot of COVID work and over the last number of years doing work relating to the migrant crisis in New York. And so the company was doing a lot of work with emergency response, right? Us being an ambulance company at heart, a medical transportation company at hard, we were mobile and dynamic in that way. And that was what was needed to respond to some of these emergencies. But really, the goal of the company has evolved into meeting patients where they are in an evergreen way, tackling their health and their chronic conditions in an evergreen, proactive way. And that's where the company has evolved. In Q1 of this year, that was the first quarter in years where the company did not have any COVID revenue or migrant-related revenue. We were providing medical care to the migrants that were being bused to New York. We didn't have any of that type of revenue. We had about $76 million of revenue in Q1 of this years, all of which was comprised of our medical transportation revenue and the Care Anywhere portfolio, as I say, bringing care to where it's needed. So that was an exciting moment for us. It was the sort of first quarter and people got a chance and investors got a chance to see the business for the components that are evergreen and proactive and providing care where it's needed. And that was a big, big milestone for us? Yeah. So let's move on to medical transportation. So this is your largest, most established vertical. Can you talk a little bit about the utilization environments there? What's driving the growth today? And also just the competitive environment within medical transportation? Yeah, so medical transportation Innovation has gotten a lot of excitement recently. I know we were talking about one of our peer companies, I'd say. AMR just went public a couple months ago, and we're cheering them on as well, of course. So I think really medical transportation is evolving. Patients need to get to the care facilities and care settings that they need to get to to receive efficient care. As I mentioned, we've been doing it for over a decade now. And the real genesis for us to bring innovation to the space was really, how can we use technology to become more efficient? How can we used technology to help the system? And that's basically what we set out to build over the last 10, 11 years. We built a platform that's embedded within Epic where a discharge nurse can literally click a button and, just like Uber, see exactly when the ambulance is going to arrive to pick up the patient. That is a really magical experience for a discharge nurse. If you think back, it used to be when you ordered an ambulance or medical transportation, you'd call the first company on the list, hey, can you come pick up my patient now? Great, we'll be there in an hour. You didn't really know, are they going to be there an hour and 20 minutes? Are they going be there and 40 minutes? Maybe they weren't available to pick up the patient. You'd call a second one on the left. Now with us, we have our platform. It's directly embedded within Epic and they click a button and they could see exactly when we're arriving. And the other pieces we've approached the market in a very different way we're not we're contracting with major hospital systems to provide medical transportation for their entire population and this is a big aspect because you can imagine if a hospital called up an ambulance company and said hey can you come pick up a patient they didn't have such great insurance maybe they're busy they didn have any insurance maybe not available but for us we help the hospital system manage the patient we contract in a way that we align incentives so that we can help them manage the patient flow and that has been a big big sort of breath of fresh air to the customers we work with we work as some hospital systems like New York City Health and Hospitals Mount Sinai Jefferson we work with mainline health we work methodist we work a lot of great hospital systems that use our software, Northwell, and we help them manage that patient flow. And that integration between software and services is very unique. I think that's a winning strategy. We can talk more about it, but there's a lot of companies out there that are just doing the software, but they can't provide you with the services, or there are antiquated companies providing services, but they don't have the technology. And that's kind of our unique value proposition is we bring both to bear, both the platform and the services all integrated into one seamless experience for the facility and the patient. Yeah, so you mentioned you take all types of payers. We've had a couple of changes in the market recently with the HIC subsidies expiring, Medicaid challenges with SDP payments. Can you talk a little bit about how your payer mix has shifted over the last year or so? Yeah, for us, really, we contract first and foremost either with the insurance companies directly or with the hospital systems. I'll tell you that there's a lot of strain on the system right now. The hospital systems are definitely worried about expenses and the reimbursement rates that they're going to be getting. Certainly we believe there's going to be a lot of, many fewer population on some of the Medicaid plans. And so as a result, what patients are going to end up in the hospital. The question is, do they have Medicaid or do they not have Medicaid? Do they have insurance or do we not have insurance? The hospitals are going have to grapple with how they're going to provide services for those patients. And so that's really why we exist. We're there to help them either mitigate that, we try to keep patients out of the hospital, right, when they don't need to be there. And I'll tell a personal story in a second. And, of course, if the patient does need to Be there and needs to be transported out upon discharge, we help them do that efficiently. So I think, you know, to be more and more efficient, one of the things is really CMS's goal to reward outcomes. And the upfront reimbursements are so low. you have no choice but to use technology to drive down the cost, otherwise you won't be successful. So it's pretty clear what the industry and what CMS is trying to do. They're trying to incentivize providers like us and hospital systems and insurance companies that we work with to drive the cost down, to improve outcomes, and to reward companies and providers for doing that. We've all had experiences where we've gone to the doctor or taken a child to the hospital, and there's just test after test. providers get rewarded the sicker and sicker you get the more and more times they visit the hospital the more more times a visit a doctor's office and the system has to change to where actually companies like like mine companies like ours are successful the healthier the patient is that's what CMS I believe is trying to do we sit at the intersection of that and I think you're going to see more and that come down come down the pipe here I think also in some cases you're gonna see pressure on rates but in some case is going to be higher incentives I think CMS is really pushing more preventative care. They're increasing the G codes on preventative care. They're improving reimbursements on proactive screenings and things of that nature, all with an effort to improve outcomes, which will ultimately drive down the total cost of care. So that's really kind of the piece of the strategy we're focused on. Yeah, so I guess sticking on medical transportation just for a little bit, So what do you think customers are prioritizing when they're selecting their vendors? And then what do YOU think is driving your ability to continue to take share in this market? So I think, first and foremost, the customers we work with are prioritising the transparency of the service delivery. When are we going to be there? How often do we arrive on time? How quickly can we move the patients and free up the bed for the next patient? That's the key. So, for example, when we're ordered, when medical transportation is ordered through us, alerts go out across the hospital. The housekeeping team is notified, now it's time to go make up the room for the next patient. The intake team is certified, hey, the bed is freed up for the Next patient. The discharge nurse knows exactly when to get the patient ready because they know exactly when we are going to be arriving. So that transparency and understanding each piece of the service delivery is very, very valuable to the hospital system, and that's what the tech platform enables them to do. I also think the quality of the service is very, very important. And so they choose us based on that. They typically don't choose us based on price. We're not going to be the lowest cost provider. We're there to provide medical transportation to the entire patient population that they serve. Oftentimes that requires the hospital system to invest alongside us. Part of the issue has been that all the ambulance companies happen to be busy when a patient that doesn't have insurance or has low reimbursement insurance needs to be transported. We'll be there to take that patient. We want to provide great care and great access for all, but then the incentives have to be in line between the facility and the provider. So a lot of cases we have a program where we call like a dedicated fleet where our ambulances are dedicated to that facility and we'll transport any of the patients they need to transport and we will bill insurance if we're able to collect our daily minimum. The hospital system doesn't owe us anything. If we're not able to collect, then the hospital pitches in the shortfall. And that aligns incentives. The other way we align incentives is we'll tell the hospital when we're going to arrive to pick up the patient. We show up there and the patient's not ready. We just have to wait around. Everybody loses. The patient loses, the hospital loses, and we lose. You know, we couldn't be the only ones to lose in that scenario where we're just waiting for the patient to be ready. So that's the key, aligning all the incentives where the hospital system knows they can have reliable, great quality transparent transportation and patient flow. We know that when we show up the patient's going to be ready so we could be really efficient and transport as many patients as we can throughout that shift throughout that day and then of course the patient benefits in a great way when there's great quality predictable transportation to get them where they need to be. That's what we've set up that's why we think we're going tobe very successful. It's great hearing about those partnerships and relationships that you have. I want to pivot to the recent acquisition of SteadyMD which had a really strong first quarter. Can you talk a little bit about how this business is operating post-acquisition and how we should think about the pipeline of new logos and existing logos from here? Yes, so we're very excited. We have a very talented team that's joined the company in SteadyMD. They had a record quarter in Q1. They're on a really great trajectory for the rest of this year. They continue to sign incredible customers and partners in the pharmacy space and the digital wellness space. and I think you know we're very excited. The other piece that is very foundational, this idea of going to deliver care in the home, we don't send a doctor, we'll send an MD to the home. We don't send a nurse practitioner or physician's assistant into the home there's just too much drive time, there's too much time in between the patient interactions. So what we do which is very unique is we'll find the medical assistant or an LPN into the home they're the hands eyes and ears in the home that's able to vaccinate a patient that's they will take a swab take a lab sample take a screening and remotely virtually is the higher-order clinician and that's the steady MD network so we've really through this acquisition we've done two things they we've brought a great you know virtual care practice 50 state into the company and we've created this network where now the steady MD clinicians are overseeing the DACO visits in the home. And that four, five, 600 clinician network is enabling us to scale the in-the-home visits way faster. So that's why we're so excited about this. And we think, look, you have to be able to provide care in every modality, virtually, remotely, and in person. And there are so many companies that could do it virtually, but they can't be in person. There are companies that can be in-person, like the doctor's office, but they don't do the digital or remote well. We are building the competency to do all of it under one clinical practice. And so when the telehealth visit will do, we'll do a telehealth visit. When we need to be with the patient hands-on, we have the ability to do that as well. We can't take a blood sample through a Zoom call, through a virtual visit. We can't give a patient a vaccination through a screen, but we can do a lot of things virtually. And so that's the wonderful aspect of what we're building. We're building this care anywhere platform where we can be with the patient when it's needed. We can be virtual when it'S efficient. We can Be remote. So we're monitoring the patient throughout their daily lives and we can intervene and be proactive in the moment in real time. That is very unique at the scale we're doing it. It's a very big vision, and it's really, frankly, what's needed for the health care system because if the health system keeps going the way it's going, where we spend 19% of GDP, I'm sure a lot of people are talking about this throughout the conference, patients are just getting sicker and sicker. And rewarding providers like ours for treating patients that just keep getting sick and sick really, really frankly makes no sense. That's what CMS is really pushing. We applaud them for that. And rewarding folks like us for the healthier the patients get, the less they're bouncing back to the hospital is really where the system needs to go to save the system, frankly, from total collapse. Yes, we talked a little bit about the flywheel of demand with the SteadyMD acquisition. So as we think about the demand trajectory and also the margin profile, how should we think About this integrating into the company and driving additional efficiencies? Yes, so that is the big aspect, that integration where the StedyMD clinical practice group. So before we acquired SteadyMD, we had our own clinical practice group. And then, of course, SteadyD came with the clinical practice groups. So now we've integrated the clinical practices group into one clinical practice group serving all the patients we see, whether they be the Steady MD patients, DACO patients, or any of the patients that we see. And again, marrying the SteADYMD network to the clinician in the home, when DACO sends a clinician to the home. That's what's going to to be driving the efficiency. So we think that's going to improve the margins. A big aspect of the company is we've been investing into the ability to bring a doctor's office into a patient's living room. That's what we've Been investing into. It's cost us money. Obviously, it's contributing to the EBITDA loss. But we think That opportunity is just such a big opportunity. But We also realized that we have to improve The margins as we go. We want to be effective and viable. And so SteadyMD allows us to Improve the margins as We go, allows us To see the patients in the home but also to serve other customers with virtual visits and that integration integrating the clinical practice groups and then integrating the competencies doc goes ability to go in the home studying these ability to be virtual now it's all under one roof and we can be very very efficient going forward yeah and just double clicking one more time into study md so there's been a little bit of focus on like some of the current logos like the online pharmacies for weight loss but can you talk about are there any other types of customers that you want to call out, or like additional logos that you would want to expand into that you think are a big opportunity? Yeah, so you mentioned the online pharmacies. That's obviously a big, with the GLP-1, you know, adoption, that's been a big growth driver for the company, and we've been at the forefront of that. I also think something that has not been talked about a lot is, well, everyone's talking about AI, but everyone's talking about AR as sort of like a replacement, or maybe to be more efficient. We actually think the clinician with AI is going to be very, very powerful. So I'll give you an example. We work with a customer today, a dermatology AI-focused company, where you can upload a picture of, let's say, a skin condition, or you can engage with AI in a chat. But ultimately, if there's some diagnosis that's needed or there's some higher-level interaction that's needed where a patient actually wants to speak to a clinician, we can unlock that. So I think it's going to be our clinicians that are making sure that the AI is making the right diagnosis. It's our clinicians are going to be sort of an off-ramp for when a patient actually does want to speak to a human clinician. And I think you're going to see a lot of marrying between the two. Today, a clinician still has to review that dermatology assessment. And so we're working with a lot AI companies to bring the clinical practice to whatever tool they're trying to build to make the healthcare system more efficient. Okay. So now that we've walked through a lot of the pieces of the business, I want to ask about the underlying demand trends that you're seeing across the portfolio in the second quarter. We've heard from some of our hospital companies one last week who said surgical volumes were down and potentially flagged a weaker demand environment. So I guess, is there any color that you can give us on demand trends throughout the second quarter so far? Yeah, so we actually, we don't play with those higher order, you know, surgical procedures. Actually, if we're doing our job well, surgical procedures will go down and sort of higher, more acute interventions will go down. And that's really, frankly, what the health care system needs. Now, of course, hospitals play a vital role. If a patient truly needs that more acute surgical procedure, then we want to be there to be able to maybe coordinate the transportation or to provide the follow-up care in the home to make sure that it's healing properly and so forth. We do all of that. So I think the demand trends we're seeing is really around the consumerization of health care. I think a lot of the wearable companies are going to get more and more into health care. I think they are doing a wonderful job with some of the diagnostics they're able to do with the wearables, but then if they truly want to take the next leap into sort of a medical device, they're going to need a clinical practice, and setting up a clinical process is not so easy to do. Certainly to do it in all 50 states is not too easy to to do, and so we're finding a lot demand there where you have the consumerization of health care, And those digital health companies that want to offer actual medical advice, medical services to their members, to their subscribers, we unlock that for them. So we're seeing a lot of growth there. I think we're also seeing a lot of growth, again, from the payer side, where they're trying to improve their MLR, they're trying to drive down costs, they are trying to reduce hospital readmissions, they're trying to improve their quality score ratings, and the only way to really do that, well, there's lots of ways to do that, but the big way to do that is drifting, that are unattached, that are going, you know, without the care, we're helping them address that. So we are seeing a big tailwind there, for sure. And so, you know, we're continuing to widen the scope that we're providing in the home. We're trying to meet patients before they end up in a hospitalization. We're try to meet patient within that 30-day readmit window so that we can see them in the home, maybe redress that incision site, maybe make sure that they don't bounce back to the hospital. We work with a very large payer in California where they've been giving us the LACE score patients, the length of stay acuity, chronic condition patients on a scale of 1 to 10. They've been giving us, I think, on average, 9.2 out of 10. So these are the highest acuity patients. Our patient population they've been giving up has been bouncing back to the emergency department 60% less. So because, again, we're following up with their care plans in the home. So I think this idea of meeting patients where they are is playing out, and the payers, the majority of the customers we have on the payer side want to expand with us this year. Okay, so maybe all the demand's just shifting out of those acute settings. So you've outlined a path to profitability this year. So how should we think about the key drivers and what the puts and takes are going to be? Yeah, so this is a big, big aspect for the company. You know, we shared on our last earnings call that we plan to break even in the back half of the year. And it's really a factor of three, obviously, key components. The first is on a quarterly revenue basis, we want to achieve the $80 to $85 million. And we feel like that's the critical need, the sort of watermark that we need to get to on a revenue side in order to have the scale that we need. And so in Q1, I mentioned we did about $76 million of revenue. So we feel like we're quite close to that. And of course, I mentioned a lot of the growth that we're seeing throughout the company. And so that is sort of within reach, if you will. So that revenue base, you know, that's one component of it, about $80 to $85 million of quarterly revenue. Then on the gross margin side, we feel like we need to be in the 34 to 35%. In Q1, we were at 31.6 adjusted gross margin. So we feel like, again, we have about 200 or 300 basis points to 400 basis points that go there. That's going to be driven by being more and more efficient in our delivery, reducing overtime hours for our staff, reducing shift bonuses, being much more efficient, again in the field with the medical assistants and the licensed practical nurses alongside the study and the clinicians and driving that gross margin up. And as the mobile health portfolio takes more and more of the revenue component, that will drive margins up with it. So as an example, our mobile phlebotomy offering has about 55% gross margins. Our remote patient monitoring practice has about 60% gross margins. So, as those continue to grow and become a bigger component of the revenue base, it will also take gross margins with it, and then we need to cut about four to five million of SG&A spends per quarter. We did a very large reduction in force recently, so we took some costs out of the business, and we're continuing to work with the vendors that we work with to sort of pare back some of the spending there, and мы think that we can get that done. Okay, so that was some really good detail there on mix versus scale versus operating efficiency. As we think about 27 and beyond, once we're past that break-even point, what do you think are the biggest levers going forward? Yeah, I think it's going to continue to be, from a growth perspective, it's gonna continue to the Care Anywhere platform. I think we're gonna continue to have very nice growth in those components. We think the Care-Anywhere platform, again, the virtual care, the care in the home, the mobile lab, the remote patient monitoring aspects will grow about 30% to 40% year on year. Again, medical transportation less. And so as that grows, that'll be a continuing lever for that. I think we'll also continue to expand with the payers we work with. You know, right now we work with a number of wonderful, fantastic name-brand payers. I know some of them will be at the conference. And so we work with those payers, and we think over time we're going to be thoughtful about it. There are a lot of markets that those payors want us to go to. So I shared, and it's always, like you said, it's a balance there, right? So we have a payer that we work within California. We recently expanded with them to Kentucky and New Mexico. There's other states we could expand with them. But we also want to be mindful new markets require new investment, which require perhaps strain on the EBITDA. So we're being very thoughtful about that. We're expanding to new states in a very measured way, and we think we're expanding the states in a way where we can do it profitably quickly. We announced a couple of weeks ago that we just launched mobile phlebotomy services in southern Florida, actually in the neck of the woods. And we did that in partnership with one of the major labs, and we did it in a way where we were able to scale the staff, you know, cheaply and quickly, and the demand was already there for us. We didn't have to generate it, so we think we're going to be profitable very quickly in that endeavor here in southern Florida. And so that's the way we're kind of, you now, be scaling the business. Yeah, so we touched a little bit on the CMS access model a little earlier. I'd love to go more in depth into both CMS access, but also are there any other CMS or regulatory proposals that we should be aware of as it relates to your business? Yeah, so the access model was a big program that CMS launched. Essentially what that model is trying to incentivize is a much lower upfront basically reimbursement for a preventative, you know, care. And if you're successful in achieving health outcomes, which I'll give some examples of, then you get sort of incentive payments and bonus payments. And that was a big move by CMS. They put out an RFP. I think a lot of companies responded to it. They ultimately ended up choosing 150 to participate. We are one of the 150 that was selected. And I think time will tell. We will launch in a measured way where patients can be enrolled into our practice as part of the access program, and we will provide preventative care exactly like we're doing today and try to drive outcomes. And so I think we will see more programs like that from CMS. I think that's the only real solution. I mean, I think part of the aspect that people in healthcare don't talk enough about is in order to improve health outcomes, most of the time you need a long-term view, right? Patients that have chronic conditions, it takes time to impact their health outcomes. It takes time to improve their condition. And our system is set up in a very short-term way. I may have one insurance provider this year, and next year I might change my insurance provider. I might work for a company where I have one assurance, and then I go and work for another company that has a different insurance. So how can an insurance company actually invest to make me healthier, try so hard this year to maybe perhaps help me if I'm struggling with a chronic condition, only to see me go to another health insurance company if I were to change roles or change jobs or change insurance companies. And so that's the problem the system has. The only one that can solve that is CMS. And so I think that is CMS's responsibility, and I think they're going to continue to look there, all the conversations that we have around this from people that are in that orbit, advising in that space are telling us that CMS is pushing more and more to develop programs that are incentivizing that because otherwise the healthcare system is completely doomed. Even for us we're a self-insured employer on the health side and we try so hard to help our employees, our team members that perhaps are high utilizers and have chronic conditions and look, we feel a moral responsibility to try to help them, even if they are to go to move on to another company and have another insurance provider. But we see it. You have to have a long-term view to impact someone's health, but the insurance industry and the healthcare industry is set up for short-term incentives. And so that has to be solved. Everybody's talking about all these things with AI and everything else. You can invest in anything you want. If it does not improve health outcomes over a period of time where you could actually make a return on that investment, which is how we're set up which is the way it should be right i'm going to work so hard to make a patient healthier only to see them go to another provider or go to another insurance company and that insurance company is going to get all the benefit of all the investment i made into that patient then that has to change so i think that's the types of programs you're seeing the heat is quality scale is a big part of that where insurance providers are incentivized to improve outcomes and have higher you know star ratings i think it's about something like 40% of the plans, you know, improvement in their reimbursement rate if they were stars, and they're missing out on that. And 5% is a meaningful, you know, premium, you know, reimbursement to get from CMS, Uplift. So I think that's where the system's going. It has to go that way. The only one that could actually push incentives like that is CMS, and I know, you know, from the access program as an example, they're really looking towards that. Okay. I've got one quick housekeeping modeling question. So fuel costs have been a big area of focus with the conflict in the Middle East. They weighed on earnings in the first quarter, but it seems like costs have come down. Is there any updated framing you can give us and how we should be thinking about that into the second quarter and the rest of the year? Yeah, it's funny, Sarah. So obviously we have, I should have mentioned at the onset, we deliver health care. How do we do it? We have 1,000 vehicles. We have 4,000 clinicians in the field, all meeting patients where they are, taking patients to where they need to get to. And last year we were bragging that we drove like 11.5 million miles. And the team was, you know, we were talking about it, and I said, hey, guys, actually we should be bragging about how much fewer miles we can drive. And so that's part of the efficiency. If we didn't have our tech platform, I'm sure we'd be driving a lot more. But as part of that, we purchased about 270,000 gallons of gasoline each quarter. It's pretty significant. And so for every dollar increase at the pump, we see about a 35 basis point margin hit. So for every $35, again, 35 basis points margin hit, our biggest component in the business is really the vehicles and the labor, not the gas. But we'd love it if the gas prices went lower, but it's about, you know, for every dollars, about 35 basis pints. Sometimes people think like it would end up impacting our business more. It will be a headwind for us in Q2. We're seeing much higher gas prices in Q3. We think that will persist. But then we think, you know, hopefully the bait's in the back half of the year, which will help on the gross margin side. The other piece that we're doing in order to offset things we can't control, like gas prices, is to invest in the things that we can control, like automating a lot of the aspects of the business. So I mentioned on our last earnings call, we have an efficiency portfolio that includes a lot of automating and automating into the business, And so, for example, on our pre-billing, annual pre-bullying function where we would go in and see, you know, probably pre-authorization to see if the patient has insurance, we're going to be able to collect, notify the hospital system of that, and now we're using AI to do that as an example. We were using a lot of human capital to coordinate patient schedules, visits, rescheduling, confirming appointments, and Now we're Using AI more and more to do that. So we are going to do the best we can to procure the gas for the cheapest possible way, but understanding we can't control the price. But we are absolutely, like, sleeves rolled up on the aspects of the business that we can control investing in automation so that we Can Improve the Margins, which is a big facet of what we're doing to get to break even in the back half of the year. Yeah, and so how should we think about cash flow and capital needs over the medium term, and how should be think about capital allocation given where we are today? Yeah. So first and foremost, I've been resolute in terms of the capital allocation. We're going to continue to fund the growth of the business and fund the capabilities of the business. And we think that there's a lot of opportunity for us in the pipeline that we have in the business, and the existing customer base we have. As I mentioned, we have the majority of our health plans are looking to expand with us this year. So that's really first and foremost where the capital location priority will sit. And then I think we have ability to access capital. We have a line of credit today that we're looking to slightly modify and have access to capital to help fund the growth of the business going forward. Okay. And we've got about two minutes left. So I just want to go over, what do you think investors are most misunderstanding about the dot-go business today? Well, that's a good one, Sarah. Thank you for asking that. So again, sometimes people look at our stock chart and say, Lee, what am I missing? You have a $300 million healthcare services and technology company going and meeting patients where they are, which is, you know, again, one of the other pieces we didn't talk about is the federal government is also earmarking about $50 billion to help improve access to patients. You're doing all this. You have great scale. You have 1,000 vehicles, 4,000 clinicians. You know, you're operating across all 50 states. You Know, what are we missing when we look at the stock charts? I think we, over the last couple of years, have really been digesting the comps from the COVID and the migrant. Like I said, I think Q1 was the first quarter where we didn' t have any of that. But in Q1 of last year, we had about $35 million of migrant revenues providing services to the humanitarian crisis in New York relating to the migrants. So when you look year over year, right, was the business growing or is it not? Again, when you take out the migrant revenues, it is. But when you see it on that screening process, those year over years have been tough for us. So that continues. I think we'll have some of that in Q2, but as we go throughout the year, that will abate. And I also think, again, I think people are looking at really where we're investing into and they want to see the progress in the Health Care at Any Address, Care Anywhere program. I think we are showing that. We certainly showed that with all the volumes being up in Q1. We'll continue to show that as we go throughout the year here. And then as we hit that profitability threshold, I Think we're going to be celebrating that. Yeah, so we're super excited to watch the rest of the story from here and reaching breakeven profitability. Thank you so much for the time and attending our conference today. Thank you, Sarah. Appreciate it. Thank You to the Goldman team.